August 2012
-
AstraZeneca has announced that it will acquire Takeda’s respiratory line for $575 million. According to the company, about 200 Takeda employees will transfer to AstraZeneca as part of the deal. The company is citing the… Read more . . .
-
Turing Pharmaceuticals CEO Martin Shkreli has been arrested by the Federal Bureau of Investigations for securities fraud involving illegal stock transactions when he was CEO of Retrophin Pharmaceuticals. Retrophin fired Shkreli in September 2014 and… Read more . . .
-
Capsugel has announced that it will acquire CDMO Xcelience and micronization services provider Powdersize in order to “enhance Capsugel’s position as a leading provider of innovative dosage forms and solutions to healthcare customers around the… Read more . . .
-
Novartis, East Hanover, NJ Job requirements Independently, provide and drive strategic and operational global CMC regulatory direction and documentation for complex projects/products covering development, registration and approval/post approval activities as assigned. As a senior member… Read more . . .
-
UK-based CDMO Pharmaterials Ltd has announced the promotions of Chris Landeg to VP, Operations and Martin Wing-King to Director, Business Development and Project Management. The company also said that it has hired Yogesh Davé as… Read more . . .
-
Teva has acquired exclusive marketing and commercialization rights to Egalet Corporation’s Sprix ketorolac tromethamine nasal spray in Israel, Gaza and the West Bank, Egalet has announced. Sprix nasal spray is used for the short-term treatment… Read more . . .
-
Dry powder inhalation products developer Pulmatrix has appointed former Civitas Therapeutics CEO Mark Iwicki as chairman of its board of directors, the company said. Iwicki has also previously headed Blend Pharmaceuticals and Sunovion and currently… Read more . . .
-
Swedish device developer Iconovo has received a $350,000 grant from Swedish innovation agency Vinnova for continued development of the company’s ICOone unit-dose disposable dry powder inhaler, the company said. Iconovo, which is located at the… Read more . . .
-
RODES, Inc. and Ligand Pharmaceuticals have announced global license and supply agreements for three products in development using Ligand’s Captisol formulation technology, including intranasal budesonide/azelastine for the treatment of allergic rhinitis. RODES will pay all… Read more . . .
-
Aptar Pharma will introduce its new DF30Plus metering valve at this year’s Drug Delivery to the Lungs conference, the company said. The DF30Plus is based on the company’s widely-used DF30 metering valve and features a… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland